Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 23

Trial Status

Completed2
Terminated2

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT02735512Terminated
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
No Evidence of DiseaseStage II Bladder CancerStage III Bladder Cancer+2 more
PrincipalinvestigatorStart date: 2016-03-01
NCT01240629Phase 1/2Completed
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Hormone-resistant Prostate CancerProstate CancerRecurrent Prostate Cancer+1 more
PrincipalinvestigatorStart date: 2010-11-02
NCT01338792Phase 2Completed
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
Hormone-resistant Prostate CancerRecurrent Prostate Cancer
Principalinvestigator
NCT01469338Phase 2Terminated
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
DiarrheaHormone-resistant Prostate CancerRecurrent Prostate Cancer+5 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Stage IV Prostate CancerProstate CancerRecurrent Prostate Cancer+1 more
Similarity Score9%

Rahul Aggarwal, MD

University of California, San Francisco

Related
22 trials

Shared therapeutic areas:

Prostate CancerStage IV Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)Sanofi
Similarity Score4%

Kevin Volpp, MD, PhD

University of Pennsylvania

Related
12 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score2%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score2%

Neha sharma, PhD

Warwick Research Services

Related
11 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score2%

Zhaohui Zhu, MD

Peking Union Medical College Hospital

Related
19 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score2%

Barbara Murphy, MD

Vanderbilt-Ingram Cancer Center

Related
14 trials

Shared therapeutic areas:

Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Charles L. Loprinzi, MD

Mayo Clinic

Related
14 trials

Shared therapeutic areas:

Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score2%

Mario Sznol, MD

Vion Pharmaceuticals

Related
14 trials

Shared therapeutic areas:

Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT02735512PrincipalInvestigator

MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer

No Evidence of DiseaseStage II Bladder CancerStage III Bladder Cancer+2 more
Terminated
NCT01240629Phase 1/2PrincipalInvestigator

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Hormone-resistant Prostate CancerProstate CancerRecurrent Prostate Cancer+1 more
Completed
NCT01338792Phase 2PrincipalInvestigator

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Hormone-resistant Prostate CancerRecurrent Prostate Cancer
Completed
NCT01469338Phase 2PrincipalInvestigator

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

DiarrheaHormone-resistant Prostate CancerRecurrent Prostate Cancer+5 more
Terminated

All 4 trials loaded